Inhibition and regression of atherosclerotic lesions

Area of Science:

• Cardiovascular Research
• Gene Therapy
• Metabolic Disorders

Background:

• Atherosclerosis was traditionally viewed as irreversible lipid buildup.
• Emerging evidence highlights the dynamic and reversible nature of atherosclerotic lesions.
• Dyslipidemia poses a significant risk for cardiovascular disease.

Purpose of the Study:

• To explore liver-directed gene therapy for treating dyslipidemia.
• To investigate the potential of gene therapy in managing atherosclerosis.
• To assess the long-term effects of gene therapy on the atherogenic process.

Main Methods:

• Utilizing liver-directed gene therapy strategies.
• Employing experimental animal models to study atherosclerotic lesion dynamics.
• Analyzing the long-term impact of therapeutic gene expression in the liver.

Main Results:

• Gene therapy demonstrates effectiveness in treating patients with dyslipidemia unresponsive to conventional treatments.
• Long-term hepatic gene therapy significantly suppresses inflammation associated with atherosclerosis.
• Therapeutic gene expression profoundly influences the progression and remodeling of atherosclerotic lesions.

Conclusions:

• Liver-directed gene therapy represents a promising therapeutic avenue for dyslipidemia and atherosclerosis.
• Gene therapy offers a dynamic approach to managing cardiovascular disease risk factors.
• Further research into gene therapy's long-term effects can elucidate its full potential in cardiovascular medicine.